The indication for T-DM1 as a second line treatment in advanced-stage HER2-positive breast cancer, and more recently for early-stage patients with invasive residual disease, are based on data from the EMILIA, TH3RESA and KATHERINE phase III clinical trials [19,30,96,149,150] (Table 3). The gene discussed is ERBB2; the disease is breast carcinoma.